MATERIAL CHANGE REPORT

THIS REPORT IS FILED UNDER British Columbia (section 85(1) of the Securities Act; **Ontario** (section 75(2) of the Securities Act); **Alberta** (section 146(1) of the Securities Act).

Item 1. Reporting Issuer

Biomax Technologies Inc.
11491 Kingston Street
Maple Ridge, BC
V2X 0Y6
Tel: 604-465-1040 Fax: 604-465-3323

Item 2. Date of Material Change

March 11, 2003

Item 3. Press Release

A Press Release was disseminated by Canada Stockwatch and Market News on March 11, 2003.

Item 4. Summary of Material Change

Biomax sells Patent for Fluorescence scope system for US$180,000.

Item 5. Full Description of Material Change

See attached press release.

Item 6. Reliance on (section 85(2) of the Securities Act, British Columbia), section 75(3) of the Securities Act, Ontario), (section 146(2) of the Securities Act, Alberta).

Item 7. Omitted Information

None.

Item 8. Senior Officers

For further information please contact Brian Lock, CEO, at 604-465-1040.

Item 9. Statement of Senior Officer

The foregoing accurately discloses the material change referred to herein.

Dated at Maple Ridge, British Columbia, this 11th day of March 2003.

“ *Brian Lock*”
(signed) Brian Lock, President & CEO

FOR IMMEDIATE RELEASE
Biomax Technologies Inc.

BIOMAX SELLS PATENT

Vancouver, British Columbia, March 11, 2003 – Biomax Technologies Inc. (Toronto Venture Exchange: "BIX"), announced today that it has sold its United States Patent #6,021,344 "Fluorescence scope system for dermatologic diagnosis" to the August Research Group for US$180,000.

Biomax Technologies Inc. also announces that it intends to submit proposals to settle debt with its creditors, subject to the approval of all appropriate authorities.

For more information, please contact:

Brian Lock, CEO
Biomax Technologies Inc.
Phone: 604-465-1040
Fax: 604-465-3323